Judah Frommer
Stock Analyst at Morgan Stanley
(3.92)
# 645
Out of 5,005 analysts
182
Total ratings
59.4%
Success rate
7.07%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $71 → $101 | $83.92 | +20.35% | 3 | Sep 12, 2025 | |
| TRVI Trevi Therapeutics | Initiates: Overweight | $18 | $9.88 | +82.19% | 1 | Aug 21, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $25 → $26 | $23.80 | +9.24% | 2 | Jul 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $46 → $43 | $26.41 | +62.82% | 2 | May 9, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $22 → $24 | $10.43 | +130.11% | 2 | Mar 14, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | $31 → $22 | $37.62 | -41.52% | 3 | Feb 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Underweight | $8 → $6 | $8.55 | -29.82% | 2 | Jan 13, 2025 | |
| ACLX Arcellx | Maintains: Overweight | $81 → $106 | $85.07 | +24.60% | 2 | Nov 6, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $35 | $17.04 | +105.40% | 1 | Oct 8, 2024 | |
| MURA Mural Oncology | Initiates: Overweight | $13 | $2.08 | +525.00% | 1 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $2.74 | +9.49% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $2.49 | +1,506.43% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.73 | +651.45% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $47.00 | -36.17% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $25.56 | -10.02% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $65.37 | -23.51% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $22.64 | +522.79% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $5.23 | +72.08% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $30.67 | -28.27% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $5.56 | +25.90% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $9.22 | -13.23% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $35.65 | +29.03% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $3.30 | +112.12% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $54.92 | +0.15% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $157.16 | -70.73% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $102.57 | -52.23% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $915.38 | -59.58% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $76.18 | -59.31% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $82.15 | -7.49% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $100.21 | +81.62% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $89.98 | +18.92% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $131.42 | -27.71% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $17.38 | +3.57% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $156.05 | -25.66% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $92.70 | -59.01% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $105.93 | -79.23% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $66.30 | -47.21% | 9 | Apr 29, 2020 |
ABIVAX Société Anonyme
Sep 12, 2025
Maintains: Overweight
Price Target: $71 → $101
Current: $83.92
Upside: +20.35%
Trevi Therapeutics
Aug 21, 2025
Initiates: Overweight
Price Target: $18
Current: $9.88
Upside: +82.19%
Apellis Pharmaceuticals
Jul 2, 2025
Maintains: Equal-Weight
Price Target: $25 → $26
Current: $23.80
Upside: +9.24%
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $26.41
Upside: +62.82%
REGENXBIO
Mar 14, 2025
Maintains: Overweight
Price Target: $22 → $24
Current: $10.43
Upside: +130.11%
Galapagos NV
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $37.62
Upside: -41.52%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $8.55
Upside: -29.82%
Arcellx
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $85.07
Upside: +24.60%
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $17.04
Upside: +105.40%
Mural Oncology
Apr 4, 2024
Initiates: Overweight
Price Target: $13
Current: $2.08
Upside: +525.00%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $2.74
Upside: +9.49%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $2.49
Upside: +1,506.43%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.73
Upside: +651.45%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $47.00
Upside: -36.17%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $25.56
Upside: -10.02%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $65.37
Upside: -23.51%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $22.64
Upside: +522.79%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $5.23
Upside: +72.08%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $30.67
Upside: -28.27%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $5.56
Upside: +25.90%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $9.22
Upside: -13.23%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $35.65
Upside: +29.03%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $3.30
Upside: +112.12%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $54.92
Upside: +0.15%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $157.16
Upside: -70.73%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $102.57
Upside: -52.23%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $915.38
Upside: -59.58%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $76.18
Upside: -59.31%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $82.15
Upside: -7.49%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $100.21
Upside: +81.62%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $89.98
Upside: +18.92%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $131.42
Upside: -27.71%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $17.38
Upside: +3.57%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $156.05
Upside: -25.66%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $92.70
Upside: -59.01%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $105.93
Upside: -79.23%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $66.30
Upside: -47.21%